AGIO - Earnings call transcript Q4 2017 | Agios Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Agios' Fourth Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Kendra Adams, Senior Director, Investor and Public Relations.

Kendra Adams

Candice. you, Thank and call. everyone Agios' quarter fourth Good welcome conference XXXX morning to

You our by and Medical on summarize today’s who Investors for review Financial clinical our our could slides access Chief who Officer, fourth call an XXXX; are will on development Chief XXXX will Q&A. David update Hirsch, our will Chief Scientific year Dr. agios.com. Dr. Chief Officer, Andrew full Bowden, Executive Hoerter Officer today who and and business section will Officer available website, going Scott for With Agios also Commercial our Officer, activities; call and me for updates our results; the key Dr. Steve Schenkein, milestone of provide financial Chief the to be our Biller, Chris

filings from we that everyone could include statements. to Actual get events call by as statements with various factors, with forth Factors we a including we materially Risk expressed the like started, results most those will of Before of any on risks, make this any other forward-looking forward-looking those our in and other Form SEC may remind and section XX-Q statements or implied uncertainties the the recent filed I’d SEC. make differ set result that and

representing forward-looking I'll only In over update specifically addition, as any as subsequent today the revise with or statements. views of as views should any David. And that, call made and be disclaim on our forward-looking to date. upon to our call statements of represent obligation not relied any turn this We any

Dr. David Schenkein

and to us set important and our medicines novel everybody morning January open targets. a development of research When metabolic against good today. and out strong of creating capable labs XXXX, organization and thanks for delivering in Kendra, joining we build Thanks,

AML, of first progress discovered laid need we on this product our drug to Most with within bring It's notably past based FDA to on believe of XXXX. preclinical way from medicine European on AML the from months. approved submitted internally As therapies and year, in a in relapsed therapies. milestones in accomplishments January, patients trials, to IDHIFA, in proud approval vision. new across organization second single ultimately approval also new XXXX refractory few clinical regulatory acceptable. ivosidenib FDA drug portfolio. We're We've focused treatment successfully secure that XX at a was the the for this AML within and also we're agency in In These to submit August. XXXX assuming year, in could developed the relapsed our the of result our available packaged we of tremendous to X a our this refractory Agios and precision we rare quarter, authorization is repeating achieving mutation quarter application the we the cancer have that to have for we need new approved ivosidenib Starting two ivosidenib. success on in reflect marketing clinical the fourth on AML then discover to already third options out IDHX end planning trial market. build discovered key for a for Phase medicines our are portfolio, and we're once well application medicine in a At accomplished XXXX, which this and a to

advance work ongoing ivosidenib into and tumor the AML important to on will front solid you update line have setting, Chris shortly. We which

science the a Phase escalation This from newest cancers on as clinic to a is initiate with first-in-class deletion. is to metabolic trial most gene this elegant inhibitor track enter research frequent the AG-XXX program cancer the target clinical latest dose to program and quarter. X utilize Our MATXA

two continue for pyruvate disease we kinase develop our beginning the with treatment modifying to first and deficiency, AG-XXX to trials this ACTIVATE-T quarter pivotal work next. Moving and ACTIVATE

first research deliver in multiple or unveiled pipeline enzyme treatment XX is hematologic for January depth time poised for the dehydrogenase drug malignancies. the of of to months. most of is our advanced the which Finally, investigational over inhibitor applications the an research dihydroorotate The program DHODH we next the new metabolic

transformational Day expect our year for potential goals to Investor and options. work. We the clinical our and over organization in for to I portfolios wholly-owned turn the in clinical us, support the to first our second now but commercial research an Chris also with XXXX will treatment the strategies advance for goals be suddenly supporting this and to R&D program activities. fourth highlighting submit approval review time our continued to commercialization for set an an it is our clinical We of quarter. will the in robust pre this the plan and This clinical of host Agios to waiting product, to addition of quarter an to portfolio. are ambitious a growth better important patients discuss who these exciting for

Dr. Chris Bowden

full of trials. be ivosidenib plan standard early or presented and agent to I’ll AML, our both chemotherapy by of patients. American demonstrating showed important broad help the for These efficacy. sets respectively diagnose reviewing from relapsed/refractory Society signs Annual encouraging a care our Meeting combined first two and Phase we’re start a time recent X IDH David. role also the Phase Data support Hematology with clinical with that combination strategy we two in will results progress single setting patients. December, the Both X demonstrated induction where that inhibition Thanks data development data enable encompasses At trial of azacitidine. large in frontline standard in as the a combination AML, in enasidenib in ivosidenib dose executing of frontline newly us can that number in for

IDHX ongoing chemotherapy. for Phase study not AGILE first mutant with eligible X who The intensive for are patients is AML

intergroup-sponsored Based AML evolving a for IDH end both new induction treatment new the that regulatory to and free with preparing is trail the which the primary combining chemotherapy, expected standard survival. is on point inhibitors fourth landscape, is trial also the initiate in We’re event quarter.

in most IDHX all addition not AML ASH a newly recommendation AML the for therapy. induction survival azacitidine rapidly overall is at XA several X all with the the IDHX new evaluating Phase The therapies exciting to or XXXX, recommend change single XX ASH. AML to have end to for Phase induction AML or of standard that receive well. diagnosed our the important Phase enasidenib at as We plan in or older and in presentation relapsed/refractory from AML of the submitted IDHX as data to or for combination this free the ivosidenib targeted event with treatments. patients current present survival of now agent a recognize recently data trial Guidelines patients NCCN at We intensive been remission data clinical for agent are mutation. who chemotherapy submit trial point, Category of potential declined trial with plan trial patients mutated single with AGILE with ASCO. guidelines updated presentation We’re to relapsed/refectory Enasidenib approved X testing year. for The combination ivosidenib changing treatment AML landscape candidates X updated The mutated disease role the IDHX presented and new

to shift part approval mutated proud AML. and are U.S. with of of We a IDHX be this relapsed/refractory enasidenib therapeutic

lower glioma. AML, role Beyond in ivosidenib's grade of cholangiocarcinoma inhibition IDHX to demonstrate to evaluate we in are the working potential and continuing

expect Our to Phase in next ClarIDHy treated X cholangiocarcinoma evaluating year. full and achieve patient enrollment mutant trial IDHX ongoing ivosidenib we previously is

For will this ivosidenib in perioperative glioma, we effects evaluating tissue in a brain are in trial window quarter. AG-XXX that initiate tumor

escalation patients quarter MTAP tumors enrolled also only AG-XXX, lymphoma. suppressor solid or X for will and the Consistent CDKNXA our with stage a with selection tumor patients X solid presentation inhibitor Phase trial. tumor have Phase with have this submitted deletion gene MATXA our ASCO. strategy, AG-XXX most this trial expected data molecule begin recent the gene our tumors to We in patient of is dose clinical the at whose be for

turning least complement enroll second this kinase transfusions. clinical quarter. to in two transfused do disease. Now begin This pediatric rare for who regularly we to study are we regular AG-XXX and diseases, launching implications patient expected pyruvate patients receive for registry us our patients their approximately To adult enroll also will global adults ACTIVATE-T quarter PEAK plan begin two at will in the plan, to of as to of XX long-term upcoming clinical years ACTIVATE trials pivotal approximately not who and to enable follow a registry are this known quarter have the deficiency. will XX

such anemias PKR Our has preclinical has sickle as and disease. demonstrated in hemolytic cell activation utility thalassemia potential other work

quarter trial AG-XXX in Phase We year to will clinical indication this expect the multiple I our initiate include development the earlier be a proof-of-concept thalassemia, we a execution with which now will clinical hand pivotal Andrew across fourth medicines year. of to trials investigation XXXX of to and we have over the broadened X financials. as it portfolio. and expand end initiate organization, in our of to in

Andrew Hirsch

will $XX then sales We of revenue guidance. of $X.X start revenue net revenue million $XX million by I our XXXX, collaboration from recognize which I'll cash our IDHIFA. of XXXX performance operating includes reviewing runway position Thanks for and Chris. of million and cover royalty

IDHIFA the XXXX, of and by X received the million metrics in We trend in this are year-over-year initiation we was quarter-to-quarter IDHIFA milestone identified revenue with Phase of growth trial. the decrease the performance sales, of earlier key The year. a encouraged $XX the the and payment upon disclosed result

development represents of by expense by clinical activities expected cholangiocarcinoma. the we NDA in cost during XXXX, on in expenses activity result largely XXXX and of our On XXXX. research ivosidenib program infrastructure including of XXXX from This of investments was an ivosidenib XXXX, in administrative both in a as the and driven frontline $XX and $XXX R&D our basis AML from preparation and IND AG-XXX. of and in were million IDHIFA operating $XX and increase inhibitor MATXA enabling million, increase trial million side, for increased also investment increased launch commercial launch million incurred in and increase expense an driven with $XX general capabilities year-over-year expenses.

investment role and of of research thank ability and on the low-grade Agios to provides and cash million. ivosidenib our trials activation maintaining inhibitors $XXX yearend position, to we We our please support. the deliver launch the required activities their fund in of our productive evaluation our trials cholangiocarcinoma. of lines the later with AML to mutant time this while of focus frame. business of pleased will in the strength including investors of planned important With open of frame, that, over end AG-XXX at frontline to us execution secure to business this Clinical and activities appropriately in of Further for ivosidenib other DHODH the strong our of labels PK deficiency, have INDs IND-enabling the billion net a time value questions. year. in the invest our financial inhibitor operator, discovery thalassemia driving for allow clinical on our all role proceeds capital, $XXX January through ability which balance over all IDH least our multiple in as pivotal two this of balance, XXXX. which This million to of of We're in just offering for result glioma, engine, expect of us from the across anemias, the AG-XXX, hemolytic early our now development clinical Turning $X fall cash development and financial exploration is for PK

Operator

with Instructions] Cowen. first And our Eric question Schmidt comes [Operator from

is open. line Your

Eric Schmidt

of the the regulatory of you're priority Maybe Do in review? couple questions, acceptance? What's ivosidenib have prior review quick think or -- just an expecting I mentioned a you expect approval you I QX. guess status

Dr. David Schenkein

Thanks Eric. here. David

out the we and announced receive that month is on we when put yet was will which this based we to that it, what QX we we with IDHIFA. haven't timing So, announce with -- and we saw based receive This expect do that.

until we you but will same know. the that, have assuming that we we’re have let we will when so, And

Eric Schmidt

over to plans submit for on EMA IDHIFA, And to partner then are behalf of approval there at your some Celgene point?

Dr. David Schenkein

that as and So the as by plan submit this for end call we previously to ivo that announced morning the of Eric, we announced on this year. you heard you we've know

year anything, but fair assumption expect a haven't think announced as to we it’s we filing So, this that them I well. be

Operator

Thank you.

from of Markets. Next question Kennen comes MacKay Capital RBC

is open. Your line

Kennen MacKay

the just duration to rational to more having one, from maybe the on you save just a walk overall and bit point there color as that on still Chris, the maybe time of secondary, be an helpful? shift end of us PFS. would survival Is Can trial there? through the maybe the clinical a OS

Dr. Chris Bowden

a terms development that free point was patients benefit. of They last to and I was clinical for approvals certainly One end think for of survival provable So, as for for regulatory several year Mylotarg things better in year FDA's overall at new you, pretty of AML the ASH important who with going event AML. free important change were any as survival recognized event a and used presentation. for the of marker being are

of that the it treatment potential yet that them that's your motivator it crossover randomized effect free any have of offer of can the control more that into both to is and to can do you measures, in And come therapy. a active is study, we a their can interest for important the when is they free trial. is for that when have we of status, the secondary for in it there thing as on randomized one haven't the other are providers. the would And made pretty survival you know So and -- event to, when AML offers an things you measures that And any you does you crossover consider, really potential therapies be well on study, trial are to to what when patients healthcare trial event as you us always in you survival actually that decision someone as testing the couple trial issue a the be mutation for survival the space. truly of so

put as some thinking the mix those into we of considering free event of the So are for of that study. the AGILE are things we survival this about

Kennen MacKay

to the talk little not just it bit months, AML, updated aren't are who drug treatment kind through patients necessarily progressing one experiencing you're six Does different in some out again Guideline earlier though I than clinical months benefits. enasidenib they show label the on is certain of progression that benefits came And six you this Can responders advocated other the promoting this recommended so just until patients treatment, then belated with experiencing and for least at question on which this NCCN which help us little about, aiming how months that really that? minimum of a bit response could the guess or who in to of maybe six us for in deal? treatment just walk or

Dr. David Schenkein

a we NCCN Hi, have here. sell talk David about, then on doing come Chris bit Kennen, Maybe and and can just about necessary Guidelines. to we what back are Steve talk the if I'll the little side Steve?

Steve Hoerter

months would treated FDA we you're promote consistent recommending What in that six seal to So your the patients, the with statement. is of to label, so be a minimum patients disease be or progression. writing having until for

Dr. Chris Bowden

Kennen, here. it's Chris

with look at much drug, update look to and treatment up of docs the which are think continue label an and who thing common overt progression. relapsed/refractory ended the is almost to more that you investigators they can for main -- which go the to out is are there the NCCN the I sign AML when mutation. Because patients as response understand we at talk going that that you using is there's they label in months, language time think our the be when best six as in the why I and until IDHX

an use already. the drug think Guideline, IDHIFA it's NCCN I using indicator were think for really is impact with overall overall us the that people of for and clear pretty having who how to I it So, are the

Kennen MacKay

the ASH. the this I how therapy if And for and the of piece for Thank quite more in Could five of of and on something is bit That’s color who Chris or IHDX maybe these may previously patients mutant the I recommendation may question the duration Thanks that that, the is more final talk opportunity candidate response one I about actually, patient of that you sort conditions here? guess market the guidelines and language the got up patients. there. of a we at relates induction it you're size patients not of declined frontline therapy, to and you. Should where very right relapsed/refractory of And much. was be about they a particularly brought intensive guidelines. taking be but talk who versus be guess Got which to of to relapsed/refractory what opportunity? would patients market size could one in for just who the months appreciate about, well expect sort range you And me. three just the

Dr. David Schenkein

David Kevin, Thanks, here.

this population because high from number, diagnosed offered hypomethylating is talked So, we hard them the may or before. that you even about AML therapy an that essentially as can't agents exact get of getting I of give induction are but either cases. it. in not our standard there It's estimate age to illnesses preclude or as would be comorbid today being some XX%

we to think for enasidenib for standard trials very ivosidenib, population not both the have clinical a and for it’s So, for therapy. sizable eligible the be for patients eligibility

we're will label demonstrate where those promote there population the to it to think do to IDHIFA is receive and we can But that in we we going and population, out overtime only sizable the patients. more So hopefully it's benefits for label more hopefully for a think obviously, ivosidenib. we that

Operator

our And Thank Yatin next of SunTrust. Suneja you. question comes from

open. line Your is

Yatin Suneja

differently setting? when FDA regard needs with European be happen the ivo. now is you guys that And relapsed/refractory anything compare then? What to at the for there on specifically the between filing with and Just looking to might European

Dr. David Schenkein

here. David it's Yatin,

about before EU package end the conversations submitting have at of for the be in sitting of assuming go of As front the then we those we FDA with data discussions approval. sufficient regulators that will year. that is now said the whether And traditional we will well this

on can't data I same will I details we be comment not So have around the really or adequate package assessing of Celgene for looking IDHIFA. thing doing any what we but they really are believe is is and for, exactly whether currently

Yatin Suneja

then do work that I preclinical And responses? with Could it on biomarkers those the us MTAP one tell like be question correlate maybe you how few question. in that study the in then do of have have like some and program. done I and looking the might Got biomarker you that more you've a

Dr. David Schenkein

Yes, Scott let so, talk of doing. work some I'll about to the biomarker we’re

Dr. Scott Biller

Yes, discovered this just a really step take to XX% case, a another where It's we're metabolism. excited And we've cancer a approach of to tumors. in Agios back, covers about so example validated novel this all of using in about it drug program. first

So, the turns selection, in patient in is of these out suppressor that with terms tumor CDKNXA. is tumors gene MTAP it lost co-deleted the which

So and have out that on, -- on these suppressor Once, next have the patients a validated patients they patients they loss loss will that's generation also in are MTAP it standard will IHC. trial, be panels. sequencing tumor will CDKNXA by be the a now if that's of

the epigenetic So selection is other but response MTAP Obviously, using. and MTAP, between and that's we main factors, we're a will actually different loss. looking to see the lot that biomarkers is genetic correlation of main here the strategy biomarker patient be a

Yatin Suneja

you focus say be other bigger lung, more let position? of focusing would bigger indication have some Or indication? the we you like tumor do MTAP terms and your orphan-type on types, where the bladder for would or And tumors in then on smaller

Dr. Scott Biller

we've basket about a part on dose too trial talked to is X be the it Yatin, trial. Phase speculate escalation Yes, of the that, as early will

clinical pharmacodynamic move be will glioblastoma and PK that based virtually we included we preclinical decisions as dictated by get parameters already tumor their we be docs. make has will they by will that and on established eligibility, and different which and So safety data. indication largely and to then both any than because in Once genetics treated be other will about are forward passed Scott mentioned

haven't as yet get and closer. we And so, we articulated we will

Yatin Suneja

one you prevalence for and question, estimate final recently program, then updated this PKD incidence we saw just one the I the on disease. the And mean

understand is or Just how wide new still how estimate, the new up are from range to X.X with just XX,XXX pretty, you come trying mean understanding with the maybe you comfortable X million? the pretty to I almost prevalence numbers? or in help like is So the since one us the

Dr. David Schenkein

Hoerter Yatin. am thanks to I going address Steve to ask that. Yes,

Steve Hoerter

terms range very prevalence As disease of what for a the that or fact very-very times, we here us literature the the certainly in the literature deficiency the pyruvate references often of in literature, guide references broad are where rare in and few of of range diseases prevalence the disease, case in genetic such terms of pretty incidence kinase a in see true the in to is. broad

been doing I and disease the work leaders has of refinement all at So, is the certainly range estimates the that work, that X,XXXX. we've X,XXX to in a provided, to of from lead finding around prior stage say talking estimate, comfortable would with a thought And we lot patient we've to feel this aggregate education, of us field. at that which

Operator

our And next Rama comes Morgan. you. from Anupam of JP question Thank

Anupam Rama

of ivosidenib thinking the Maybe few how sales heading should be walk there? next into the the we you over quarter-over-quarter, And us expense what side about sort could how infrastructure will approval? here change months through the

Andrew Hirsch

Steve on talk then touch unfold. the after about infrastructure you maybe expense I’ll So can how the will and side

to sales think be JP the we on So Morgan at quarter. as mentioned board that, is going I first conference force largely so in your

expense later for QX but or run the the material XXXX. think that probably look a be G&A at to as additional produce of fully will is There slight where be a and bake the in largely in excreta, likely to going I most we loaded may expense. probably in promotional first that year, So some XXXX rate but be SG&A you quarter, can is QX kind increase

Steve Hoerter

is sales infrastructure, mid the representatives organization of That in the get the of to the in and XXs terms we in launch in be number of team then IDHIFA of as as that the go terms ivo. to hired this support sales the to with process later typical and So being Andrew and full together is ready now launch, so on speak out mentioned, the and ivo year. we've trained promote Celgene management ready for

Operator

our John Newman Thank question you. next And of Canaccord. from comes

Your line is open.

John Newman

a few Just questions, is. question first the

looking survival you survival, survival, event expect that as you versus ask they overall I'm this free be I'm benefit And approval, maybe that if see now overall your and for relatively here? the mentioned kind end wondering looking will a at for the FDA the primary you imply does initial need point. be of You will larger to versus to curious what confirm survival as data am after I just to might the effect? curious, to

Dr. David Schenkein

made topic, here. the potential Chris some survival. year. its comments to all looking that the We're to want you to make that event In the remind overall last do is of on I John, that change and things of space at survival. primary Hi, point that end earlier, some the Really reviewing happened interest I free

oncology magnitude to one it -- you you with of that data? to discussion And expect do to regards point, you what end this yes. provide a trial effect have of we is a as study part. a we be regulators AML you X compelling to or might you survival primary think that a has you the is, important last Phase investigators, want clinically have the remains for of If part point in or the as to change very answer with -- a endpoint treatment a event certainly What's most And type provide if survival -- then, the when powered change. your question information albeit of make show? effect survival your part about when contemplate Now So free in which secondary were that end other other treatment to randomized have see? survival, any and yes, do it's and the to even around with indication for event

John Newman

question the program PKD. additional one in AG-XXX on And

study do the that just carefully built you very I'm a for have dosing. allow this if curious, you built have will just you in, am I here I control to the So strategy but assuming in wondered design

you you if reductions to for may clinical So of if a short mitigate any period pop suspend example, just up? that's you or in curious can I'm the needed safety some needed built dose dosing concerns such time, make for if to that that

Dr. Chris Bowden

of in that have a yes, in and there event we protocols guidance that of an you would both dosing terms down, capture Yes, of and that and compositely. John, data to again. Chris direction investigator to a oversight whether will so take pause we guidance lot up lots want the have or dose very

Operator

Thank you.

from Our next question comes Goldman Terence of Flynn Sachs.

Terence Flynn

You guys the of trial are XXX, ASCO X from the at Phase guiding to first data tumors. clinical solid

a also, relative us if IDHIFA with higher you hear see than XXX and actually the here activity Just And level to saw are PK? wondering, tumor setting? solid of based of hoping and to we profile can remind to you the ivosidenib on ivo some the data preclinical

Dr. David Schenkein

Terence, here. David

little we of was So in backup turns both preclinical on let inhibitor, the on it more and some as IDHX. me remind out maybe you can designed bit brain-penetrant data showed that a molecules of as comment inhibitor that a of And XXX ivosidenib, XXX. IDHX Scott the XXXX an

Dr. Scott Biller

SNO have all we the both so of and disclosures the again that triple the Yes, aspects that characterizing on meeting discovery of the at preclinical molecule. AG-XXX, of data

be than could therapeutic has significant we designed reduction. in to the exposure more David very models, the at ivosidenib. brain-penetrant ivosidenib significantly XHG So was show as XXX preclinical But mentioned,

pharmacodynamic our that's course Of biomarker.

reduction more XHG tumor that brain therapeutically could is to in behind the in With up were with the relevant XX%. brain tumor up in models to see XHG reductions we where in AG-XXX, doses profound So, measure blood barrier. brain the actually to able can we ivosidenib. of XX% And see we even

drug. in be one you on as about to goals accurate sense impact as dose a of brain and AG-XXX So, study in the so ivosidenib study XHG you've and very brain we're perioperative the this study in humans main resection, perioperative get levels the going comparing of heard well get of where of before that's to can samples

really next molecules step the that's in the of low-grade So these glioma. development for

Operator

And you. from question comes Young next of Suisse. Credit Thank Alethia our

is now Your line open.

Alethia Young

you'll based MTAP of how it guys kind the with rate the cadence? of on on thoughts program. on about expectations Have One number any how little decided with you some findings ACTIVATE-T a the just people? of talk you data Or communicate do and second And question, general is? ACTIVATE? the is launching initial around enrollment the the have associated the just robust limit And bit

Dr. David Schenkein

Thanks Alethia.

will Chris medical when other we right be have MTAP and it then to how need have clinical that the to the right quickly enough will on the that I make bit since meeting, We'll we as to at starts that venue. new I'll a about many be. So, about It And little obviously there. of know, track achieve activate. ACTIVATE. doing our just don’t can't we appropriate that different of will any bring record Maybe really we’re have talk Chris program, bring doses, sense data predict and going talk can no a a when will than and to coverts as is

Dr. Chris Bowden

Chris here. Hi,

respectively. main recruit the of first to to both of issue and So, in the possible. our to rapidly these ACTIVATE-T guidance, in up quarter second running so bring this we’re year and on as is them track studies to and is And get then ACTIVATE as and them according

to finding active looking the these organization really the of as that quickly in all rapidly and trials as of we are done patient we've now data possible, getting that these as site running global studies possible. a across we're forward the as up recruit as and get so lot So work all and can operational Phase,

Operator

the closing for I back remarks. Schenkein over that and for concludes Dr. you today. like Thank any to our turn would to question-and-answer-session conference

Dr. David Schenkein

Thanks. seeing market Thanks and precision bring day. be look genetic I patients, life and you difference disease year and we employees also the and to second just tremendous thank many all in who of as oncology a Have across I'd clinical important Agios caregivers, for XXXX their good like in broad the to trials. to all today, we a medicine will for work and a participated an make positions the all our joining at the us second to at to want our to the dedication passion and to execute of a you for forward patients' Day. Investor Agios our portfolio. take rare thank

Operator

and program. Ladies does for thank the participating you today's in conclude This gentlemen, conference.

have day. disconnect. Everyone a You great may all

Agios Pharmaceuticals (AGIO) 14 Feb 182017 Q4 Earnings call transcript